Program Description:
Bispecific antibodies (BsAbs) are a class of immune therapies that are approved for various cancers, initially in hematological malignancies and now in solid tumors. Most currently available BsAbs engage T cells by targeting CD3 and a tumor antigen. Though primarily approved for previously treated patients, their use has moved to front-line settings. As BsAbs approvals expand, their varying mechanisms, toxicity profiles, and monitoring requirements add complexity to treatment decisions. Differences in target selection, structure, and immune engagement affect dosing, toxicity, and patient selection, presenting challenges for oncology pharmacists in clinical decision-making. In community oncology, incorporating BsAbs is crucial for patient access, though logistics and experience may hinder adoption. Additionally, the integration of BsAbs introduces new operational considerations such as complex dosing strategies, monitoring requirements, multidisciplinary coordination, and biomarker-driven patient identification. These factors can create workflow challenges across both academic and community oncology settings as clinical teams adapt to the expanding use of these therapies. Oncology pharmacists play a central role in developing treatment workflows, coordinating care delivery, and supporting patient access. This session reviews strategies for effective BsAb implementation, focusing on patient selection and toxicity management. Speakers will guide participants in translating emerging clinical evidence into implementation strategies that support safe and efficient delivery of BsAbs.
Target audience: Oncology Pharmacist
Type of activity: Application
Release date: June 18, 2026
Expiration date: August 18, 2026
Time to complete activity: 1.0 hour
Learner level: Intermediate, Advanced
Fee: Free
Educational
Objectives:
At the completion of this activity, participants will be able to:
- Differentiate bispecific antibody classes by mechanism and structure to inform dosing approaches, anticipate toxicity profiles, and guide patient selection
- Apply monitoring and supportive care strategies tailored to individual bispecific antibodies to manage treatment-related toxicities
- Optimize clinical workflows to support the safe and effective implementation of individual bispecific antibodies in oncology care settings